AI eye test to prevent vision loss from diabetes
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This study uses artificial intelligence to check for early signs of diabetic eye disease in people who haven't had an eye exam in the past year. It aims to catch problems early and prevent vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 or type 2 diabetes
- You have no known diabetic eye disease
- Your main health insurance is Medicaid
- You haven't had an eye exam in the last year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses an artificial intelligence (AI) system to check for diabetic eye disease (retinopathy) during your regular doctor visit. It aims to detect problems early so you can get treatment sooner.
This trial tests a new AI-powered, do-it-yourself screening system for diabetic retinopathy. It may help find early signs of eye disease in people who haven't had an eye exam in the past year.
This trial uses an AI system to test if it can find early signs of diabetic eye disease (diabetic retinopathy) in people with diabetes. If you have diabetes but no known eye problems, the AI might help catch issues early.
This trial tests whether an artificial intelligence (AI) system can help doctors diagnose diabetic retinopathy, an eye condition caused by diabetes. If you have diabetes and haven't been treated for it yet, you may be able to join.
This study tests an AI platform that checks for diabetic retinopathy, a common eye problem in people with diabetes. It aims to see if the AI can spot signs of damage early, so you can get treatment sooner.
This study tests an AI system that automatically detects signs of diabetic retinopathy from eye photos. It aims to see if the AI can accurately identify these signs to help with early detection.
Hear when a new Diabetic Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.